Overview of Dr. Wang
Dr. Rui Wang is an oncologist in Montvale, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Bergen. She received her medical degree from West China University of Medical Sciences and has been in practice 24 years. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 15 doctors at Memorial Sloan Kettering Bergen who specialize in Oncology. She has more than 20 publications and over 500 citings.
Office
225 Summit Avenue
Montvale, NJ 07645
Education & Training
West China University of Medical SciencesClass of 1996
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2015 - 2026
NJ State Medical License 2018 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Early Use of Prone Position in ECMO for Severe ARDS Start of enrollment: 2019 Nov 01
Publications & Presentations
PubMed
- 6 citationsPhase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year ...Rui Wang, Lillian M. Smyth, Neil M. Iyengar, Sarat Chandarlapaty, Shanu Modi
The Oncologist. 2019-08-01 - 43 citationsA phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breas...Komal Jhaveri, Rui Wang, Eleonora Teplinsky, Sarat Chandarlapaty, David B. Solit
Breast Cancer Research. 2017-08-02 - 218 citationsExpression of GARP selectively identifies activated human FOXP3+ regulatory T cellsRui Wang, Lina Kozhaya, Frances Mercer, Alka Khaitan, Hodaka Fujii
Proceedings of the National Academy of Sciences of the United States of America. 2009-08-11
Press Mentions
Behind the Study: HER3: A Vital Target in Cancer TreatmentOctober 13th, 2023- New Findings in JNCCN Illustrate Pathway for Screening High-Risk Individuals for Pancreatic Cancer in PRECEDE StudyApril 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
